These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 6417018)

  • 21. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis.
    Pedersen SS; Espersen F; Høiby N; Jensen T
    J Clin Microbiol; 1990 Apr; 28(4):747-55. PubMed ID: 2110181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pseudomonas aeruginosa flagellin and alginate elicit very distinct gene expression patterns in airway epithelial cells: implications for cystic fibrosis disease.
    Cobb LM; Mychaleckyj JC; Wozniak DJ; López-Boado YS
    J Immunol; 2004 Nov; 173(9):5659-70. PubMed ID: 15494517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection.
    Tosi MF; Zakem-Cloud H; Demko CA; Schreiber JR; Stern RC; Konstan MW; Berger M
    J Infect Dis; 1995 Aug; 172(2):453-61. PubMed ID: 7622889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonspecific immunoglobulin synthesis and elevated IgG levels in rabbits immunized with mucoid exopolysaccharide from cystic fibrosis isolates of Pseudomonas aeruginosa.
    Pier GB; Elcock ME
    J Immunol; 1984 Aug; 133(2):734-9. PubMed ID: 6234359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia. A new prophylactic principle.
    Johansen HK; Cryz SJ; Hougen HP; Moser C; Høiby N
    Behring Inst Mitt; 1997 Feb; (98):269-73. PubMed ID: 9382750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of outer membrane proteins as target antigens of Pseudomonas aeruginosa Homma serotype M.
    Yokota S
    Clin Diagn Lab Immunol; 1995 Nov; 2(6):747-52. PubMed ID: 8574841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association with phagocytic inhibition of anti-Pseudomonas aeruginosa immunoglobulin G antibody subclass levels in serum from patients with cystic fibrosis.
    Shryock TR; Mollé JS; Klinger JD; Thomassen MJ
    J Clin Microbiol; 1986 Mar; 23(3):513-6. PubMed ID: 3082922
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Brao KJ; Wille BP; Lieberman J; Ernst RK; Shirtliff ME; Harro JM
    Infect Immun; 2020 Aug; 88(9):. PubMed ID: 32631918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alginate--its role in neutrophil responses and signal transduction towards mucoid Pseudomonas aeruginosa bacteria.
    König B; Friedl P; Pedersen SS; König W
    Int Arch Allergy Immunol; 1992; 99(1):98-106. PubMed ID: 1336422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibodies to cell envelope proteins of Pseudomonas aeruginosa in cystic fibrosis patients.
    Fernandes PB; Kim C; Cundy KR; Haung NN
    Infect Immun; 1981 Aug; 33(2):527-32. PubMed ID: 6792080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Pier GB
    Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.
    Theilacker C; Coleman FT; Mueschenborn S; Llosa N; Grout M; Pier GB
    Infect Immun; 2003 Jul; 71(7):3875-84. PubMed ID: 12819072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The immunoevasive activities of Pseudomonas aeruginosa. Relevance for cystic fibrosis.
    Buret A; Cripps AW
    Am Rev Respir Dis; 1993 Sep; 148(3):793-805. PubMed ID: 8368651
    [No Abstract]   [Full Text] [Related]  

  • 35. Reactivity of monoclonal antibodies to Pseudomonas aeruginosa isolates from hospitalized adults and patients with cystic fibrosis.
    Torensma R; Fluit AC; Verhoef J
    Clin Infect Dis; 1994 Jul; 19(1):11-4. PubMed ID: 7948511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospects for a mucoid exopolysaccharide vaccine for the prevention of infection due to mucoid strains of Pseudomonas aeruginosa.
    Baltimore RS
    Antibiot Chemother (1971); 1985; 36():147-56. PubMed ID: 3923912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients.
    Meluleni GJ; Grout M; Evans DJ; Pier GB
    J Immunol; 1995 Aug; 155(4):2029-38. PubMed ID: 7636254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections.
    Pier GB; Small GJ; Warren HB
    Science; 1990 Aug; 249(4968):537-40. PubMed ID: 2116663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of polymorphonuclear leukocyte chemotaxis by the mucoid exopolysaccharide of Pseudomonas aeruginosa.
    Stiver HG; Zachidniak K; Speert DP
    Clin Invest Med; 1988 Aug; 11(4):247-52. PubMed ID: 2971496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Host defenses in patients with cystic fibrosis: modulation by Pseudomonas aeruginosa.
    Speert DP
    Surv Synth Pathol Res; 1985; 4(1):14-33. PubMed ID: 3927464
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.